ArticleEpilepsia open2026
Economic burden and cost determinants of epilepsy in Georgia: A longitudinal cost-of-illness study.
Article in Epilepsia open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveTo assess the economic burden, cost components, and individual-level determinants of outpatient epilepsy care in adults in Georgia.
methodsThis longitudinal study of epilepsy-related costs in adults with active epilepsy attending a tertiary epilepsy centre in Tbilisi collected clinical and sociodemographic data over 6 months. Direct and indirect costs were analyzed using descriptive statistics and multivariate regression.
resultsMedian total epilepsy-related costs in 351 adults (median age 31 years; 44.4% male) for six months were USD 402.22 (IQR: 293.33-578.15), with a mean cost of USD 572.54 ± 789.29, indicating a highly skewed distribution. Direct medical costs, mainly antiseizure medications, accounted for 83.5% of the mean total. Costs were similar across urban and rural residents. In multivariable analysis, males incurred lower total costs than females (CR = 0.86; 95% CI: 0.74-0.99), employment in non-professional roles (CR = 1.47; 95% CI: 1.19-1.81), health insurance coverage (overall p = 0.010), epilepsy type (overall p = 0.014), monotherapy compared with polytherapy (CR = 0.75; 95% CI: 0.64-0.88), and greater seizure frequency (per additional seizure: CR = 1.08; 95% CI: 1.05-1.11). Age showed a weak inverse association with costs, whereas epilepsy duration and disability/social benefit status were not significant predictors. Most participants incurred costs below 40% of their six-month income, although a subset faced a disproportionately high financial burden. SIGNIFICANCE: Epilepsy in Georgia imposes a significant economic burden on adults, driven mainly by medication costs, specialized services, and poor seizure control. This highlights the need for affordable therapies, optimized management, strengthened health system support, and expanded social protection. Future research needs to assess the long-term economic impact of drug-resistant epilepsy. PLAIN LANGUAGE SUMMARY: People with epilepsy often need lifelong treatment, but little is known about the financial burden of epilepsy in Georgia. We studied the cost of epilepsy care for 351 adults over six months. Most spending was on antiseizure medications and medical tests. People who had more seizures or needed more than one antiseizure medication had higher treatment costs. For most people, the cost of epilepsy care was not extremely high, but some experienced much greater expenses than others. Our findings show where the biggest costs come from and may help improve epilepsy care and make treatment more affordable in Georgia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.